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(57) ABSTRACT 
A novel organic cation transporter (OCT) gene, OCT 6, and 
use thereof is described. The OCT6 gene is preferentially 
expressed in human hematopoietic tissues, including CD34+ 
cells and leukemia cells. Its narrow tissue distribution, sub 
strate speci?city, and close homology to other cell membrane 
transporters make OCT6 an attractive target for the treatment 
of myeloid diseases. 
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ORGANIC CATION TRANSPORTER 
PREFERENTIALLY EXPRESSED IN 
HEMATOPOIETIC CELLS AND LEUKEMIAS 
AND USES THEREOF 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application is a divisional application of and claims 
the bene?t of application Ser. No. 10/849,551, ?led May 20, 
2004 noW abandoned, Which claims the bene?t of US. Pro 
visional Application No. 60/471,709, ?led May 20, 2003. 
FIELD OF THE INVENTION 
The invention relates to a gene encoding an organic cation 
transporter, OCT6, and its use as a target for the treatment of 
hematological malignancies, and in particular, leukemia. The 
invention further relates to screening methods for identifying 
agonists and antagonists/binding partners of OCT6 transport 
activity. 
BACKGROUND OF THE INVENTION 
The lipid bilayer of the cellular membrane insulates the 
intracellular milieu from exposure to hydrophilic com 
pounds. Unlike lipophilic compounds that can diffuse 
through cellular membranes, Water-soluble compounds usu 
ally require speci?c transport mechanisms to gain access to 
the intracellular space. The regulation of the tra?ic of polar 
compounds in both directions across the cellular membrane is 
a complex process involving several large families of trans 
port proteins. 
Most often in cancer research, drug transport is thought of 
as a mechanism of cellular drug resistance, as drug e?lux 
pumps such as the products of the MDR1 and MRP genes 
have been shoWn to be mechanisms of resistance to lipid 
soluble anticancer drugs. HoWever, drug transport is a tWo 
Way street, and mechanisms also exist for pumping drugs into 
cells. Forpolar, Water-soluble anticancer agents, drug uptake, 
and not drug ef?ux, is the critical determinant of cellular drug 
accumulation. 
Most cancer chemotherapy employs drugs that are lipid 
soluble that can easily penetrate the cell membrane of cancer 
cells. One advantage of using lipid-soluble drugs is that they 
easily gain intracellular access to different types of cancer 
cells, so many cancer cells appear to be initially sensitive to 
these drugs. The disadvantage is that cancer cells learn to 
increase the activity of drug ef?ux pumps in the cell mem 
brane to pump lipid-soluble drugs out of the cell, resulting in 
drug resistance. 
In contrast, potential Water-soluble anticancer drugs may 
not survive the preclinical screening process since there is a 
great deal of variability in the expression of drug transport 
genes in different types of cancer cells. Variability in transport 
gene expression may result in variability in accumulation of 
polar, Water-soluble drugs. One approach to more effectively 
utiliZe Water-soluble anticancer drugs is to identify Which of 
the doZens of transport genes are actually expressed in 
tumors. 
The importance of carrier-mediated anticancer drug uptake 
is exempli?ed in reduced folate carrier (RFC) mediated 
uptake of methotrexate (MTX). Methotrexate (MTX), a 
reduced folate analogue, is scavenged and retained in cells by 
mechanisms designed to secure folates from the environment. 
The major mechanism of MTX uptake at pharmacologic con 
centrations is the reduced folate carrier (RFC), an OAT trans 
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2 
porter With a Km for MTX betWeen approximately 08-26 
uM. Decreased RFC activity has been observed in several in 
vitro models of transport-mediated MTX resistance (Bio 
chem. Pharmacol. 11: 1233-1234, 1960). Once rodent and 
human genes encoding proteins With RFC activity Were iso 
lated, the molecular explanations for decreased RFC activity 
emerged. RFCl transfection into the transport-de?cient 
MTXR ZR75 cell line resulted in a 20-fold increase in 6-hour 
MTX uptake and a concomitant 250-fold increase in sensi 
tivity to MTX relative to control cell clones, shoWing that the 
RFCl gene reconstitutes RFC activity and has a signi?cant 
impact on MTX cytotoxicity (MoscoW, et al., Cancer Res. 55: 
3790-3794, 1995). 
In different cell lines, MTX transport de?ciency has been 
ascribed either to mutations in the RFC gene or in decreased 
expression of the RFC gene product. Several studies have 
demonstrated that RFCl gene expression is an important 
determinant of sensitivity to MTX. In in vitro studies, We have 
found that RFCl RNA levels correlate With MTX sensitivity 
in a panel of non-selected cell lines, including breast cancer 
cell lines (MoscoW et al., Int] Cancer. 72: 184-190, 1997). 
A plethora of genes With the ability to transport MTX out of 
the cell have been reported, including MRP1, MRP2, MRP3, 
MRP4, the organic anion transporters hOAT2 and hOAT3, 
and the mitoxantrone-resistance protein (BCRP/MXR). 
HoWever, despite the multitude of MTX export genes, clinical 
studies have shoWn a relationship betWeen the expression of 
RFCl, the mechanism of MTX uptake, and prognosis in 
Acute Lymphoid Leukemia (ALL) and osteosarcoma. As a 
result, RFCl expression and MTX uptake are noW implicated 
as determinants of clinical sensitivity in several types of 
tumors. Thus, the role of RFCl in mediating sensitivity of its 
cytotoxic drug substrates has become a prototype that illus 
trates the potential role of transporters, like OAT and OCT 
genes, in determination of anticancer drug selectivity and 
toxicity. 
HoWever, there is a need to identify additional channels, or 
transporters, that are found in speci?c cancers, to enable the 
targeting of different cancers With anticancer agents that are 
substrates for those transporters. 
SUMMARY OF THE INVENTION 
The present invention is directed toWards a membrane pro 
tein that functions to transport hydrophilic substances across 
cellular membranes. The protein, OCT6, is a neW member of 
the organic cation transporter (OCT) family (SLC22 gene 
family). Tissue distribution of this protein is distinct from 
other OCT protein family members; being detected in leuke 
mia, leukemia blast cells and CD34+ cells. 
In one aspect, the present invention provides a novel target 
for hematological malignancies such as leukemia, an OCT6 
transporter. 
In another aspect of the present invention there is a method 
for screening potential substrates that selectively bind the 
OCT6 transporter. The method involves contacting a cell 
Which overexpresses an OCT6 transporter gene With a test 
compound and determining Whether the test compound is a 
substrate for the OCT6 transporter. 
In another aspect, there is a method for screening potential 
anti-cancer agents in a cell overexpressing an OCT6 trans 
porter gene. The method comprises determining viability of a 
cell Which expresses OCT6 transporter gene incubated in the 
presence and absence of a test compound and identifying the 
test compound as a potential anti-cancer agent if there is 
cellular in?ux of the test compound and cell death. 
US 7,723,019 B2 
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In another aspect of the invention, a test kit is provided for 
screening candidate drugs for hematologic malignancies 
comprising a mammalian cell line or cells Which overexpress 
OCT6, a control substrate and a detectable substance. 
In still another aspect of the invention, there are immuno 
genic compositions for treating hematological malignancies. 
In a preferred embodiment, immunogenic compositions for 
treating leukemia comprise a substrate that binds selectively 
to a leukemia cell expressing the OCT6 transporter gene. In 
another preferred embodiment of the invention, the substrate 
comprises an antibody that selectively binds to the OCT6 
transporter protein. Preferably, the OCT6 transporter protein 
alloWs cellular uptake of the substrate Which then causes cell 
death. In one embodiment the substrate is cytotoxic and in 
another preferred embodiment the substrate is coupled With a 
cytotoxic agent. 
In still another aspect, the present invention provides a 
method for impairing a leukemia cell comprising contacting 
the cell With a cytotoxic OCT6 transporter protein. In one 
embodiment the substrate is a cytotoxin and in another 
embodiment the substrate is coupled to a cytotoxic agent. 
In yet another aspect, the present invention provides a 
method for treating hematological malignancies comprising 
administering to a subject in need thereof an immunogenic 
composition comprising a substrate that binds selectively to a 
cell expressing the OCT6 transporter gene. In a preferred 
embodiment the OCT6 transporter protein alloWs cellular 
uptake of the substrate Which then causes cell death. In 
another preferred embodiment the substrate is cytotoxic. In 
another preferred embodiment, the substrate is coupled With 
a cytotoxic agent. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. A. shoWs the predicted hydropathy pro?le of 
OCT6. 
FIG. 1. B. is a dendrogram shoWing phylogenic relation 
ship betWeen OCT6 (SEQ ID NO:2) and other OCT and OAT 
proteins, including, OCTN1 (SEQ ID NO:4), OCT3 (SEQ ID 
NO:5), OCTN2 (SEQ ID NO:6), OCT2 (SEQ ID NO:7), 
OCT1 (SEQ ID NO:8), OAT5 (SEQ ID NO:9), OAT4 (SEQ 
ID NO:10), OAT3 (SEQ ID NO:11), and OAT1 (SEQ ID 
NO:12). 
FIG. 2A-F. is the CLUSTLAW alignment of OCT6 and 
other OCT and OAT proteins. The bottom roW represents 
areas of consensus. 
FIG. 3. shoWs the normal tissue distribution of OCT6 RNA 
determined by RT-PCR using a cDNA panel. Only 1000>< 
(highest) cDNA concentration is shoWn. Panel A. 1, salivary 
gland; 2, thyroid; 3, adrenal; 4, pancreas; 5, ovary; 6, uterus; 
7, prostate; 8, skins; 9, peripheral blood leukocytes; 10, bone 
marroW; 11, fetal brain; 12, fetal liver. Panel B. 1, brain; 2, 
heart; 3, kidney; 4, spleen; 5, liver; 6, colon; 7, lung; 8, small 
intestine; 9, muscle; 10, stomach, 11, testis; 12, placenta. 
FIG. 4. shoWs quantitative RT-PCR for the transporter gene 
OCT6 performed With RNA extracted from peripheral blood 
leukocytes, CD34+ cells and additional hematopoietic cell 
lines. Fresh discarded buffy coats that Were tWice sorted by 
FACS using CD14 (monocytes), CD15 (granulocytes), CD3 
(T-cells) and CD20 (B-cells). Purities of 99% or better Were 
obtained. For peripheral WBC and sorted subsets, the 
averageiSD represent pooled results from samples from 2 
individuals performed in triplicate or quadruplicate. For 
CD34-selected mobiliZed peripheral blood (MPB), the 
results from each of 3 individuals are shoWn. For CD34 
selected bone marroW (CD34+-BM), the results are from one 
individual. OCT6 levels Were normalized to the expression of 
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actin RNA, as a control for equivalence of mRNA template. 
The units, in log scale, are arbitrary and based on a standard 
curve of OCT6 RT-PCR in serially diluted HL60 RNA. Unity 
is de?ned as the level of OCT6 RNA found in MOLT4 cells. 
FIG. 5. shoWs quantitative RT-PCR for the gene OCT6 
using RNA extracted from leukemic blasts obtained from 
patients at the time of initial diagnosis. OCT6 levels Were 
normaliZed to the expression of actin RNA, as a control for 
equivalence of mRNA template. The OCT6 RNA levels in 
placenta, liver, kidney and MOLT-4 cell line Were determined 
concurrently and shoWn for comparison. The units, in log 
scale, are arbitrary and based on a standard curve of OCT6 
RT-PCR in serially diluted HL60 RNA. Unity is de?ned as the 
level of OCT6 RNA found in MOLT4 cells. 
DETAILED DESCRIPTION OF THE INVENTION 
The present invention is based on the discovery and isola 
tion of a neW member of the SLC22 gene family (the OCT 
family of proteins) that is unusual for its distinct pattern of 
tissue distribution. Rather than the typical high levels of 
expression in liver, kidney or placenta, high levels of RNA for 
this transporter Were found in some leukemia cell lines, in 
CD34+ cells, and in circulating leukemia blast cells. 
All patents, patent applications and literature cited in this 
description are incorporated herein by reference in their 
entirety. In the case of inconsistencies, the present disclosure, 
including de?nitions, Will prevail. 
OCT Family 
TWo families of proteins involved in maintaining homeo 
stasis of charged organic compounds are the organic anion 
transporters (OATs) Which carry the SLC21 designation and 
the organic cation transporters (OCTs), Which carry the 
SLC22 designation (See Table 1). OATs and OCTs each have 
characteristic patterns of tissue expression, With predominant 
expression in a tissue involved in the transport of xeriobiotics, 
i.e., liver, kidney or placenta. 
TABLE 1 
Organic anion and cation transported genes 
Gene Family Gene Name Locus Link Alternative Names 
SLC21 SLC21A1 6577 
SLC21A2 6578 PGT 
SLC21A3 6579 OATP, OATPl, OATPlb, 
OATP-A 
SLC21A4 28237 OAT-K1, OAT-K2 
SLC21A5 28236 OATP2, OATP-2 
SLC21A6 10599 LST-l, OATP-C 
SLC21A7 28235 OATP3, OATP-3 
SLC21A8 28234 LST2, OATP8, SLC21A8, 
OATP-8 
SLC21A9 11309 OATP-B 
SLC21A10 28233 OATP4 
SLC21A11 28232 OATP-D 
SLC21A12 28231 LOC51737, OATP-E, POAT 
SLC21A13 28230 OATPS, OATP-5 
SLC21A14 53919 OATP-F 
SLC22 SLC22A1 65 80 OCTl 
SLC22A2 65 82 OCT2 
SLC22A3 65 81 OCT3 
SLC22A4 65 83 OCTNl 
SLC22A5 65 84 OCTN2, CDSP, SCD 
SLC22A6 9356 NKT, OATl, OAT-1 
SLC22A7 10864 NLT, OAT2, OAT-2 
SLC22A8 9376 OAT3, OAT-3 
SLC22A9 OAT4, OAT-4 
The OAT and OCT carriers result in increased cellular 
accumulation of their respective substrates, despite the fact 
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that they are carriers that mediate facilitative diffusion. For 
carriers, the degree of intracellular accumulation may not 
exceed the extracellular concentration. However, the pres 
ence of the carrier alloWs uptake in comparison to no uptake 
in the absence of the carrier, and drugs that bind an intracel 
lular target or Which are chemically modi?ed in the cells, e.g., 
by phosphorylation or polyglutamylation, may be eliminated 
from the substrate pool and not available for transport back 
across the cellular membrane. 
The ?rst ?ve members of the SLC22 family of transporters, 
OCT1, OCT2, OCT3, OCTN1, and OCTN2, have been char 
acteriZed as organic cation transporters. The uptake of many 
cations, such as tetraethylammonium (TEA), N-l-methylni 
cotineamide (N MN), choline, procainamide, amantadine and 
morphine are mediated by these polyspeci?c transporters. In 
general, these transporters are potential-dependent, but inde 
pendent of sodium and proton gradients. These genes are all 
characterized by the presence of 11 or 12 transmembrane 
domains, as predicted by hydrophobicity analysis, and all 
have a large hydrophilic loop betWeen transmembrane 
domain (TMD) 1 and TMD2. 
OCT substrates are shoWn beloW in Table 2. Tetraethyl 
ammonium (TEA) is the classic substrate for OCT transport 
ers. In addition, OCT1, OCT2 and OCT3 transport 1-methyl 
4-phenylpyridinium (MPP). Compared to OCT2, OCT1 has a 
higher a?inity for some cations (for example mepiperpheni 
dol and procainamide), a similar a?inity for others (for 
example, decynium 22 and quinidine), and a loWer a?inity for 
corticosterone (See Koepsell et al., Ann. Rev. Physiol. 60: 
243-266, 1998.). OCT3 is an electrogenic transporter for 
TEA and guanidine. Other physiologic substrates for OCT 
transporters include dopamine, histamine, epinephrine and 
norepinephrine, acetylcholine and 5-hydroxytryptamine 
(Burckhardt, et al., Am J Physiol Renal Physiol. 278: F853 
66., 2000.), suggesting an important role for these transport 
ers in the central nervous system, in addition to their role in 
hepatic and renal clearance. Interestingly, despite its cationic 
nature, recent studies have identi?ed cimetidine as a selective 
inhibitor, but not a substrate for several organic cation trans 
porters, including rOCT1, rOCT2, rOCT3, hOCTNl, and 
hOCTN2. 
TABLE 2 
OCT Substrates 
Common 
Name Gene Name Cell Type Substrate KT (uM) 
OCT1 SLC22A1 HeLa TEA 229 
OCT1 SLC22A1 Xenopus MPP 14. 6 
OCT2 SLC22A2 Xenopus Norepinephrine 1900 
OCT2 SLC22A2 Xenopus Histamine 1300 
OCT2 SLC22A2 Xenopus Dopamine 390 
OCT2 SLC22A2 Xenopus Serotonin 80 
OCT2 SLC22A2 HEK293 MPP 16 
OCT2 SLC22A2 HEK293 Dopamine 330 
OCT2 SLC22A2 Xenopus Amantadine 27 
OCT2 SLC22A2 Xenopus Memantine 34 
OCT3 SLC22A3 HeLa TEA 2500 
OCT3 SLC22A3 HRPE MPP 47 
OCTN1 SLC22A4 Fibroblasts L-Camitine 6. 6 
OCTN2 SLC22A5 HEK293 L-Camitine 4.34 
OCTN2 SLC22A5 HEK293 L-Camitine 4.3 
OCTN2 SLC22A5 HEK293 D-Carnitine 10.9 
OCTN2 SLC22A5 HEK293 Acetyl-L-carnitine 8.5 
OCTN2 SLC22A5 Xenopus L-Camitine 4. 8 
OCTN2 SLC22A5 Xenopus D-Carnitine 98 
OCTN2 SLC22A5 JAR L-Camitine 3.5 
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OCT1 and OCT2 are predominantly expressed in the kid 
ney and liver. These transporters are located on the basolateral 
surface of renal tubules and, therefore, play a role in the 
removal of organic cations from the blood. OCT3 is most 
abundantly expressed in placenta. In addition, other tissue 
speci?c roles have been implicated for these transporters. As 
noted above, OCTs may play a role in transport of endog 
enous neuroleptic substrates, and OCT3 has been implicated 
in the disposition of cationic neurotoxins and neurotransmit 
ters in the brain (Wu, et al., J Biol Chem. 273: 32776-86, 
1998). Dhillon et al. (Clin Pharrnacol Ther. 65: 205, 19996) 
used RT-PCR folloWed by functional transport studies (TEA) 
to identify OCT1 expression in a human mammary epithelial 
cell line (MCF12A). Further, the OCT1 gene has been shoWn 
to be up regulated in lactating mammary epithelial cells. 
The OCTN1 gene, cloned from a cDNA, shoWs sequence 
similarity to organic cation transporter genes, Which is highly 
expressed in kidney as Well as trachea, bone marroW and fetal 
liver. Recombinant OCTN1 expressed in mammalian cells 
exhibited saturable uptake of TEA that Was pH sensitive. 
Several others suggest that OCTN1 is a renal proton/ organic 
cation antiporter functioning at the epithelial apical mem 
brane. The uptake of pyrilamine, quinidine, verapamil and 
L-carnitine Were increased by expression of OCTN1 inXeno 
pus oocytes. 
Another OCT protein family member, OCTN2, cloned 
from a human placental trophoblast cell line, is expressed 
Widely in human tissues including kidney, placenta and heart. 
OCTN2 is more closely related to OCTN1 than to OCT1, 
OCT2 and OCT3 (Biochem Biophys Res Commun. 246: 
589-95, 1998). Transfection of OCTN2 has demonstrated its 
role in the transport of TEA and carnitine. OCTN2-mediated 
transport of TEA is sodium independent, Whereas transport of 
carnitine is sodium-dependent. The role of sodium in 
OCTN2-mediated carnitine transport not only involves the 
electrogenic gradient, but the presence of sodium also alters 
the a?inity of OCTN2 for carnitine. Germline mutations of 
OCTN2 result in primary carnitine de?ciency, a syndrome of 
progressive cardiomyopathy and skeletal myopathy. The 
symptoms associated With this syndrome are thought to result 
not only from generaliZed carnitine de?ciency from 
decreased renal carnitine reabsorbtion, but also from inability 
of cardiac and skeletal myocytes, Which ordinarily express 
OCTN2, to accumulate camitine. This syndrome demon 
strates that tissue-speci?c OCT-mediated transport is essen 
tial for accumulation of required cations in speci?c tissues. 
The present invention identi?es a neW transport protein in 
the OCT family, OCT6, preferentially expressed in leukemia 
cell lines, leukemia blast cells and CD34+ cells. The cell 
surface localiZation and the transporter function of the OCT6 
gene product suggest its usefulness as a target in the diagnosis 
and treatment of hematologic malignancies. 
As used herein, the term “antibody” refers to an immuno 
globulin molecule With a speci?c amino acid sequence 
evoked in by an antigen, and characterized by reacting spe 
ci?cally With the antigen in some demonstrable Way. 
As used herein, the term “carrier” refers to a diluent, adju 
vant, excipient, or vehicle With Which the compositions of the 
present invention are administered. 
As used herein, “compound” refers to any agent, chemical, 
substance, or substrate, Whether organic or inorganic, or any 
protein including antibodies, peptides, polypeptides, pep 
toids, and the like. 
As used herein, the term cytotoxin” or cytoxic agent 
includes any speci?c substance, Which may or may not be 
antibody, that inhibits or prevents the functions of cells, 
causes destruction of cells, or both. 
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As used herein, the term “derivative” refers to something 
produced by modi?cation of something pre-existing; for 
example, a substance or chemical compound that may be 
produced from another substance or compound of similar 
structure in one or more steps. 
As used herein, the term “fragment” refers to a part of a 
larger entity, said larger entity comprising by non-limiting 
example, an antibody, compound or substance. 
As used herein, the term “leukemia blast” or “leukemic 
8 
OCT6 (SEQ ID NO:1) Was ?rst identi?ed as a potential 
OCT gene by assembling and sequencing ESTs as described 
in Example 1 (amino acid sequence of OCT6 is SEQ ID 
NO:2). The gene sequence proved to be identical to the 
recently submitted cDNA OKBl (GenBank AF268892) sub 
mitted by M. Okabe and T. Abe, incorporated herein in its 
entirety. It is also contained Within the submitted BAC clone 
CTA-331P3 (SEQ ID NO: 3) (GenBank AC002464) located 
at chromosome 6q21, incorporated herein in its entirety. The 
blast” refers to lymphoblasts, the abnormal immature White 10 gene has a predicted protein structure typical of transport 
blood cells associated With leukemia. proteins With tWo groups of six transmembrane domains 
As used herein, the term “monoclonal antibody” is not separated by a hydrophilic region (FIG. 1A). CLUSTALW 
limited to antibodies produced through hybridoma technol- alignment produced a dendrogram shoWing the phylogenic 
ogy. The term “monoclonal antibody” refers to an antibody relationship betWeen OCT6 and other OAT and OCT proteins 
that is derived from a single clone, including any eukaryotic, 15 (FIG. 1B). This dendrogram suggests that the distinction 
prokaryotic, or phage clone, and not the method by Which it is betWeen OAT and OCT genes, based on functional studies, 
produced. obscures the common origin of both families of transporters. 
As used herein, the term “pharmaceutically acceptable car- The actual CLUSTALW alignment of these genes is shoWn in 
rier” refers to a carrier that may be administered to a subject, FIG. 2 and demonstrates multiple regions of conservation 
together With one or more liver protecting agents and one or 20 among all of these genes. 
more mushroom poWder or extract of the present invention, Next, according to the methods described in Example 3, 
and Which does not destroy the pharmacological activity quantitative RT PCR analysis of the expression of OCT6 Was 
thereof and is nontoxic When administered in doses su?icient performed, along With the expression of other OCT genes, in 
to deliver a therapeutic amount of the compound. 50 cell lines. The results are shoWn in Table 3. The tWo highest 
As used herein, the term “substrate” refers to a substance, 25 expressing cell lines for OCT6 in this panel Were tWo leuke 
compound, agent, antibody or derivatives and/or fragment mia cell lines, HL60, a human promyelocytic leukemia cell 
thereof, acted upon by the OCT6 transporter protein (e.g., a line, and MOLT4, a human acute lymphoblastic leukemia 
substance thatistaken acrossthe cellular membrane by action (T-cell) cell line. There Was only a loW level of expression 
of the OCT6 transporter protein). detected in most of the other cell lines. 
TABLE 3 
OCT expression in 50 cell lines ofthe NCI Drug Screen 
No. Cell Line source OCT1 OCT2 OCT3 OCTN 2 OCT6 
1 CCRF-CEM Leukemia 0.7 0.7 0.2 0.1 5.7 
2 HL-60 Leukemia 0.5 1.3 0.0 0.4 716 
3 K-562 Leukemia 1.4 1.2 0.2 1.4 5.2 
4 MOLT-4 Leukemia 0.1 1.1 0.5 0.6 46.8 
5 RPMI-8226 Leukemia 2.8 2.0 0.1 3.7 6.02 
6 SR Leukemia 1.9 1.1 0.0 0.3 2.6 
7 A549/ATCC Lung cancer 1.7 1.2 161 4.3 1.2 
8 HOP-62 Lung cancer 0.8 4.8 0.6 2.4 4.1 
9 NCI-H226 Lung cancer 4.8 0.5 0.1 21.1 4.8 
10 NCI-H23 Lung cancer 0.5 0.7 0.0 0.3 5.2 
11 NCI-H460 Lung cancer 0.7 1.0 0.0 1.7 1.8 
12 COLO205 Colon Ca. 4.9 5.3 30.9 2.2 3.6 
13 HCC-2998 Colon Ca. 1.5 1.0 0.0 2.6 5.4 
14 HCT-116 Colon Ca. 1.7 2.1 0.1 2.8 9.7 
15 HCT-15 Colon Ca. 0.9 1.7 0.1 3.5 4.2 
16 HT-29 Colon Ca. 1.9 1.2 18.1 1.5 1.5 
17 KM-12 Colon Ca. 0.6 1.0 12.2 0.7 2.1 
18 SW-620 Colon Ca. 1.0 2.6 40.4 1.9 3.7 
19 SF-268 CNS Tumor 0.4 0.8 0.0 0.9 2 
20 SF-295 CNS Tumor 0.5 1.2 0.2 1.1 2.5 
21 SF-539 CNS Tumor 0.5 0.6 2.3 0.2 5.3 
22 SNB-75 CNS Tumor 0.8 1.8 0.0 0.6 2.3 
23 U251 CNS Tumor 0.8 0.9 0.0 0.6 7.4 
24 LOCIMVI Melanoma 2.9 2.1 0.1 0.4 3.6 
25 MALME-3M Melanoma 1.5 1.5 0.0 2.3 3 
26 M14 Melanoma 1.9 1.4 0.0 1.9 4.7 
27 SK-MEL-2 Melanoma 2.1 1.9 0.0 2.2 3.9 
28 SK-MEL-5 Melanoma 2.6 1.5 0.0 1.9 2.7 
29 UACC-257 Melanoma 3.2 3.6 0.0 1.1 5.4 
30 IGROVl Ovarian Ca. 4.9 5015 17.9 1.8 2.5 
31 OVCAR-3 Ovarian Ca. 1.4 0.1 0.0 2.2 14 
32 OVCAR-4 Ovarian Ca. 2.6 1.4 0.0 8.9 3.4 
33 OvCAR-5 Ovarian Ca. 3.5 2.7 105 10.0 4.8 
34 OVCAR-8 Ovarian Ca. 1.1 1.0 0.0 0.8 1.6 
35 SK-OV-3 Ovarian Ca. 3.9 1995 9.2 8.5 9.8 
36 A498 Renal Ca. 2.2 13.4 180 4.7 1.3 
37 ACHN Renal Ca. 1.1 1.1 0.7 1.2 1.1 
38 CAKI 1 Renal Ca. 3.5 2.5 4.8 1.8 2.8 
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TABLE 3-continued 
OCT expression in 50 cell lines ofthe NCI Drug Screen 
No. Cell Line source OCT1 OCT2 OCT3 OCTN2 OCT6 
39 RXF-393 Renal Ca. 1.7 1.2 3.0 0.6 1.2 
40 TK-lO Renal Ca. 3.6 5.0 16.8 2.5 8 
41 UO-31 Renal Ca. 4.4 1.6 31.2 1.2 2.3 
42 PC-3 Prostate Ca. 2.1 0.8 9.6 3.3 4.7 
43 DU-145 Prostate Ca. 1.1 1.1 3.4 1.6 3 
44 MCF-7 Breast Ca. 0.8 1.8 0.0 10.4 3.5 
45 NCI/ADR-RES Breast Ca. 1.4 1.3 1.1 2.0 2.1 
46 MDA-MB-231 Breast Ca. 1.2 0.4 3.9 4.8 1.8 
47 HS578T Breast Ca. 1.0 1.5 0.0 1.2 8.3 
48 MDA-MB-435 Breast Ca. 1.9 0.6 0.1 0.7 2.7 
49 BT-549 Breast Ca. 1.2 0.8 0.1 0.3 2.6 
50 T-47D Breast Ca. 0.7 1.1 0.1 4.2 8.7 
OCT6 is unique among the known members of OCT and 20 
OAT genes because of its pattern of tissue distribution. The TABLE 4 
pattern of expression of the OCT6 gene in the 50 cell lines I I 
suggested that its expression might be restricted to hemato- H?pwp? 
poietic tissues. The restricted pattern of expression observed 25 salnple Number Description 
for OCT6 also suggests that therapies using OCT6-speci?c , , 
. . . . 1 CML, blast cr1s1s 
substrates are unl1kely to have W1despread tox1c1ty to normal 2 CML, blast crisis 
tissues. Therefore, We examined OCT6 expression in a cDNA 3 CML, stable phase 
panel representing a Wide cross-section of normal tissues 4 CMhPIObablY Stable Phase 
. . 5 CML, accelerated phase 
accordmg to the methods of Example 4 (FIG. 3). Th1s study 30 6 ALL 
revealed that OCT6 RNA levels are highest in testis and fetal 7 ALL 
liver, With loWer but detectable levels in peripheral blood 3 AML 
leukocytes and bone marroW. Since fetal hematopoiesis 1g 25: 
occurs in the liver, it is possible that the fetal liver sample may 11 ALL 
have included both hepatocytes and hematopoietic cells. 35 12 AML 
OCT6 RNA levels Were also barely detectable in pancreatic 3 2g: 
and adrenal tissue. Unlike other OCT genes, expression Was 15 AML 
not detectable in liver, kidney or placenta. 16 ALL, biphenotypic 
To determine Whether OCT6 RNA expression in hemato- 40 i; 251 blph?notyplc 
poietic cells Was lineage-speci?c, leukocytes Were sorted 19 AML, M2 
from discarded buffy coat specimens by How cytometry, and 20 AML, M2 
. . . 21 AML, M4 
purl?ed subpopulat1ons Were exammed for OCT6 RNA 22 AML, M4 
expression according to the methods described in Example 5. 23 AML, M1 
OCT6 expression Was also examined in a population of 45 24 AML 
CD34+ cells. As can be seen in FIG. 4, the expression of 25 AML’ M4 
OCT6 Was highly enriched in CD34+ cells in comparison to 
the other cell populations. Also, signi?cant levels of OCT6 Due to the OCT6 protein’s leeatiOn On the Cellular mem 
expression (relative to MOLT4) Were found in other hemato- hrahe and its fhhetleh a5 ah intracellular transporter, the 
poietic Cell lines; U937’ a human histiocytic lymphoma Cell 50 OCT6 transporter protein has been identi?ed as a therapeutic 
line; THP-l, a human acute monocytic leukemia cell line; target Basle Pnhclples efeellular Pharmacology Suggest that 
KGJ’ a human erythroleukemia Cell line; and MV_4_11’ a increase 1n mtracellular accumulat1on W111 lead to mcreased 
human biphenotypic (B_Ce11 and myelomonocytic) leukemia mtracellular effect. Eor ant1cancer drugs, th1s pr1nc1ple has 
C en lin e‘ been stud1ed extens1vely 1n the context of l1poph1l1c drugs, 
, , , , 55 Which require no speci?c mechanism for cellular uptake, and 
The hlgh levels “OCT6 RNA In some leukemla Cell hnés export pumps such as the product of the multidrug resistance 
and CD34+' cells also ra1sed the questlon as to Whether th1s gene’ MDRL Whose overexpression of MDRI leads to 
gene Was hlghly expressed In actual leukemlas' To address increased cellular resistance by decreasing intracellular con 
thls issue: the RNA levels of OCT6 lh 25 Samples efPel‘lPh' centrations of drug (Moscow, J. A., Schneider, E. S., Ivy, S. P., 
eral leukemic cells Were measured according to the methods 60 and COWans K_ H Multidrug resistance; In; H M_ pingdos D 
set out in Example 6. The FAB classi?cation of these samples L, Longo, and B, A, Chabner (eds), Cancer chemotherapy 
are shoWn in Table 4. These results are shoWn in FIG. 5, and and biological response modi?ers. Annual 17. NeW York: 
demonstrate that the majority of specimens contained RNA Elsevier, 1997). The same principle applies to charged, 
levels for OCT6 that exceeded the level found in MOLT4 cell hydrophilic drugs of the present invention, except that the 
line, the second highest expressing cell line among those 65 determinants of sensitivity depend on uptake as opposed to 
examined, and exceed by orders of magnitude the levels 
found in placenta, kidney and liver. 
e?llux. As such, cells overexpressing an OCT6 transporter are 
likely to be highly sensitive to cytotoxic OCT6 substrates. 
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Drug Screening 
Accordingly, the present invention provides methods for 
screening potential substrates of, and potential therapeutic 
agents against hematological malignancies like leukemia that 
overexpress, the OCT6 transporter. In particular, potential 
therapeutic agents are screened for the ability to be a substrate 
recogniZed by an OCT6 transporter protein. Preferably, 
potential substrates are screened for the ability to confer 
cytotoxic effects on a cell overexpressing OCT6 transporter 
protein. More preferably, agents are screened for the ability to 
preferentially cause cellular uptake into, and cell death of, 
cells overexpressing the OCT6 transporter. Most preferably, 
the agents are screened for the ability to cause cell death of 
cancer cells such as leukemia overexpressing the OCT6 trans 
porter as compared to normal cells. 
A method for screening potential substrates of the OCT6 
transporter protein comprises providing a cell or cell line 
Which expresses OCT6 and a test compound, incubating the 
test compound and cell line and analyZing the cell or cell line 
to determine if there Was a cellular in?ux of the test com 
pound. Analysis of the cell line to determine Whether cellular 
uptake of the test compound occurred canbe accomplished by 
any means knoWn in the art. For example, a test compound 
can be tagged With a detectable label prior to contact With a 
cell and then observed under microscopy or by other means 
for its location. Non-limiting examples of labels include 
green ?uorescent protein, alkaline phosphatase, horseradish 
peroxidase, rease, f3-galactosidase, CAT, luciferase, an 
immunogenic tag peptide sequence, an extrinsically activat 
able enzyme, an extrinsically activatable toxin, an extrinsi 
cally activatable ?uor, an extrinsically activatable quenching 
agent, a radioactive element or an antibody. 
A method for screening candidate anti-cancer agents com 
prises determining the viability of a mammalian cell Which 
expresses OCT6 incubated in the presence and absence of a 
test compound and identifying the test compound as a poten 
tial anti-leukemia agent if there is a cellular uptake of the test 
compound and cell death. Analysis of cell viability can be 
accomplished by any means knoWn in the art. 
It is Well knoWn in the art that viability of a cell can be 
determined by contacting the cell With a dye and vieWing it 
under a microscope. Viable cells can be observed to have an 
intact membrane and do not stain, Whereas dying or dead cells 
having “leaky” membranes do stain. Incorporation of the dye 
by the cell indicates the death of the cell. The most common 
dye used in the art for determining viability is trypan blue. 
Viability of cells can also be determined by detecting DNA 
synthesis. Cells can be cultured in cell medium With labeled 
nucleotides (e. g., 3H thymidine). The uptake or incorporation 
of the labeled nucleotides indicates DNA synthesis and cell 
viability. In addition, colonies formed by cells cultured in 
medium indicate cell groWth and is another means to test 
viability of the cells. 
Identi?cation and/ or observation of cells undergoing apo 
ptosis can be another method of determining cell viability. 
Apoptosis is a speci?c mode of cell death recogniZed by a 
characteristic pattern of morphological, biochemical, and 
molecular changes. Cells going through apoptosis appear 
shrunken, and rounded; they also can be observed to become 
detached from culture dish. Thermophological changes 
involve a characteristic pattern of condensation of chromatin 
and cytoplasm Which can be readily identi?ed by microscopy. 
When stained With a DNA-binding dye, such as H33258, 
apoptotic cells display classic condensed and punctate nuclei 
instead of homogeneous and round nuclei. 
The hallmark of apoptosis is the endonucleolysis, a 
molecular change in Which nuclear DNA is initially degraded 
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at the linker sections of nucleosomes to give rise to fragments 
equivalent to single and multiple nucleosomes. When these 
DNA fragments are subjected to gel electrophoresis, they 
reveal a series of DNA bands Which are positioned approxi 
mately equally distant from each other on the gel. The siZe 
difference betWeen the tWo bands next to each other is about 
the length of one nucleosome (i.e., 20 base pairs). This char 
acteristic display of the DNA bands is called a DNA ladder 
and it indicates apoptosis of the cell. Apoptotic cells can be 
identi?ed by ?oW cytometric methods based on measurement 
of cellular DNA content, increased sensitivity of DNA to 
denaturation, or altered light scattering properties. These 
methods are Well knoWn in the art and are Within the contem 
plation of the invention. 
Abnormal DNA breaks are also characteristic of apoptosis 
and can be detected by any means knoWn in the art. In one 
embodiment, DNA breaks are labeled With biotinylated 
dUTP (b-dUTP). Cells are ?xed and incubated in the presence 
of biotinylated dUTP With either exogenous terminal trans 
ferase (terminal DNA transferase assay; TdT assay) or DNA 
polymerase (nick translation assay; NT assay). The biotiny 
lated dUTP is incorporated into the chromosome at the places 
Where abnormal DNA breaks are repaired, and are detected 
With ?uorescein conjugated to avidin under ?uorescence 
microscopy. 
Kits 
The present invention provides kits that can be used in the 
above screening methods. In one embodiment, a kit com 
prises a substantially isolated polypeptide comprising an 
OCT6 epitope Which is speci?cally immunoreactive With 
only test compound(s) that are substrates of the OCT6 trans 
porter protein. Binding of a test compound to the OCT6 
epitope is indicative that the test compound is a OCT6 sub 
strate. In another embodiment, a kit comprises a cell line that 
overexpresses an OCT6 transporter protein. Binding and/or 
cellular uptake of a test compound via the OCT6 protein is 
indicative that the test compound is a OCT6 substrate. Pref 
erably, the kits of the present invention further comprise a 
control compound or antibody Which does not react With the 
OCT6 transporter protein. In another speci?c embodiment, 
the kits of the present invention contain a means for detecting 
the binding of a test compound to an OCT6 epitope and/or 
cellular uptake of a test compound. For example, the test 
compound may be conjugated to a detectable substrate such 
as a ?uorescent compound, an enzymatic substrate, a radio 
active compound or a luminescent compound, or a second 
antibody Which recogniZes the ?rst antibody may be conju 
gated to a detectable substrate. 
The detectable substance may be coupled or conjugated 
either directly to the test compound (or fragment thereof) or 
indirectly, through an intermediate (such as, for example, a 
linker knoWn in the art) using techniques knoWn in the art. 
See, for example, U.S. Pat. No. 4,741,900 for metal ions 
Which can be conjugated to antibodies for use as diagnostics 
according to the present invention. Further non-limiting 
examples of detectable substances include various enZymes, 
prosthetic groups, ?uorescent materials, luminescent materi 
als, bioluminescent materials, radioactive materials, positron 
emitting metals using various positron emission tomogra 
phies, nonradioactive paramagnetic metal ions, immuno 
genic tag peptide sequences, extrinsically activatable toxins, 
extrinsically activatable quenching agents, or antibodies. 
Non-limiting examples of suitable enZymes include horse 
radish peroxidase, alkaline phosphatase, beta-galactosidase, 
or acetylcholinesterase; examples of suitable prosthetic 
group complexes include streptavidin/biotin and avidin/bi 
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otin; examples of suitable ?uorescent materials include 
umbelliferone, ?uorescein, ?uorescein isothiocyanate, 
rhodamine, dichlorotriaZinylamine ?uorescein, dansyl chlo 
ride or phycoerythrin; an example of a luminescent material 
includes luminol; examples of bioluminescent materials 
include luciferase, luciferin, and aequorin; and examples of 
suitable radioactive material include 125I, 131I, 1 11In or 99Tc. 
Immunogenic Compositions 
The present invention also provides immunogenic compo 
sitions for the treatment of hematolo gical malignancies. Non 
limiting exemplary hematological malignancies include, but 
are not limited to, Hodgkin’s disease, leukemia such as, acute 
lymphoid (lymphocytic or lymphoblastic) leukemia (ALL), 
acute myeloid (myelogenous or myeloblastic) leukemia 
(AML), acute lymphoid leukemia, biphenotypic (ALL, 
biphentoypic), acute undifferentiated leukemia (AUL), 
chronic myeloid (myelogenous or granulocytic) leukemia 
(CML), erythroleukemia, granuloxytic leukemia, lymphoma, 
monocytic leukemia, myleoma, myelomonocytic leukemia, 
myelodysplastic syndromes, non-Hodgkin lymphoma, pro 
granulocytic leukemia. 
According to the invention immunogenic compositions for 
the treatment of hematological malignancies comprise a sub 
strate recogniZed by an OCT6 transporter protein. Preferably, 
the substrate is a compound that binds selectively or speci? 
cally to a OCT6 transporter protein. In a preferred embodi 
ment, the compound binds selectively to the OCT6 trans 
porter protein encoded by a nucleotide sequence of SEQ ID 
NO: 1. The compound may be a cytotoxin or coupled or con 
jugated With a cytoxic agent. Preferably the cytoxin or cyto 
toxic agent is a chemotherapeutic agent. 
The present invention also provides pharmaceutical com 
positions. Such compositions comprise a therapeutically 
effective amount of a compound, and a pharmaceutically 
acceptable carrier. 
Cell surface proteins like the OCT6 transporter can be 
utiliZed in antibody-based targeting strategies. In still another 
aspect of the invention, antibodies can be developed by 
knoWn methods in the art against the external epitope of 
OCT6 transporter protein. In a preferred embodiment, anti 
bodies are substrates of the OCT6 protein. The antibodies 
may be polyclonal antibodies or monoclonal antibodies. 
Polyclonal antibodies to an antigen-of-interest can be pro 
duced by various procedures Well knoWn in the art. For 
example, a polypeptide of the invention can be administered 
to various host animals including, but not limited to, rabbits, 
mice, rats, etc. to induce the production of sera containing 
polyclonal antibodies speci?c for the antigen. Various adju 
vants may be used to increase the immunological response, 
depending on the host species, and include but are not limited 
to, Freund’s (complete and incomplete), mineral gels such as 
aluminum hydroxide, surface active substances such as lyso 
lecithin, pluronic polyols, polyanions, peptides, oil emul 
sions, keyhole limpet hemocyanins, dinitrophenol, and 
potentially useful human adjuvants such as BCG (bacille 
Calmette-Guerin) and corynebaclerium parvum. Such adju 
vants are also Well knoWn in the art. 
Monoclonal antibodies can be prepared using a Wide vari 
ety of techniques knoWn in the art including the use of hybri 
doma, recombinant, and phage display technologies, or a 
combination thereof. For example, monoclonal antibodies 
can be produced using hybridoma techniques including those 
knoWn in the art and taught, for example, in HarloW et al., 
Antibodies: A Laboratory Manual, (Cold Spring Harbor 
Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: 
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Monoclonal Antibodies and T-Cell Hybridomas 563-681 
(Elsevier, N.Y., 1981) (said references incorporated by refer 
ence in their entireties). 
The present invention further encompasses antibodies or 
fragments thereof conjugated to a diagnostic or therapeutic 
agent. The antibodies can be used diagnostically to, for 
example, monitor the development or progression of a tumor 
as part of a clinical testing procedure to, e.g., determine the 
e?icacy of a given treatment regimen. Detection can be facili 
tated by coupling the antibody to a detectable substance. 
Examples of detectable substances include various enZymes, 
prosthetic groups, ?uorescent materials, luminescent materi 
als, bioluminescent materials, radioactive materials, positron 
emitting metals using various positron emission tomogra 
phies, and nonradioactive paramagnetic metal ions. The 
detectable substance may be coupled or conjugated either 
directly to the antibody (or fragment thereof) or indirectly, 
through an intermediate, such as, for example, a linker knoWn 
in the art, using techniques knoWn in the art. (See, for 
example, US. Pat. No. 4,741,900 for metal ions Which can be 
conjugated to antibodies for use as diagnostics according to 
the present invention.) Examples of suitable enZymes include 
horseradishperoxidase, alkaline phosphatase, beta-galactosi 
dase, or acetylcholinesterase; examples of suitable prosthetic 
group complexes include streptavidin/biotin and avidin/bi 
otin; examples of suitable ?uorescent materials include 
umbelliferone, ?uorescein, ?uorescein isothiocyanate, 
rhodamine, dichlorotriaZinylamine ?uorescein, dansyl chlo 
ride or phycoerythrin; an example of a luminescent material 
includes luminol; examples of bioluminescent materials 
include luciferase, luciferin, and aequorin; and examples of 
suitable radioactive material include 125 I, 131I, 11 1In or 99Tc. 
Further, an antibody or fragment thereof may be conju 
gated to a therapeutic moiety such as a cytotoxin, e.g., a 
cytostatic or cytocidal agent, a therapeutic agent or a radio 
active metal ion, e.g., alpha-emitters such as, for example, 
213 Bi. Non-limiting examples include paclitaxol, cytochala 
sin B, gramicidin D, ethidium bromide, emetine, mitomycin, 
etoposide, tenoposide, vincristine, vinblastine, colchicin, 
doxorubicin, daunorubicin, dihydroxy anthracin dione, 
mitoxantrone, mithramycin, actinomycin D, l-dehydrotest 
osterone, glucocorticoids, procaine, tetracaine, lidocaine, 
propranolol, and puromycin and analogs or homologs 
thereof. Therapeutic agents include, but are not limited to, 
antimetabolites (e.g., methotrexate, 6-mercaptopurine, 
6-thioguanine, cytarabine, 5-?uorouracil decarbaZine), alky 
lating agents (e.g., mechlorethamine, thioepa chlorambucil, 
melphalan, carmustine (BSNU) and lomustine (CCNU), 
cyclothosphamide, busulfan, dibromomannitol, streptoZoto 
cin, mitomycin C, and cis-dichlorodiamine platinum (II) 
(DDP) cisplatin), anthracyclines (e.g., daunorubicin (for 
merly daunomycin) and doxorubicin), antibiotics (e.g., dac 
tinomycin (formerly actinomycin), bleomycin, mithramycin, 
and anthramycin (AMC)), and anti-mitotic agents (e.g., vin 
cristine and vinblastine). 
The conjugates of the invention can be used for modifying 
a given biological response such as inducing cell death for the 
treatment and prevention of hematological malignancies like 
leukemia. The therapeutic agent or drug moiety is not to be 
construed as limited to classical chemical therapeutic agents. 
For example, the drug moiety may be a protein or polypeptide 
possessing a desired biological activity for inducing cell 
death. Such proteins may include, for example, a toxin such 
as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; 
a protein such as tumor necrosis factor, a-interferon, .beta. 
interferon, nerve groWth factor, platelet derived groWth fac 
tor, tissue plasminogen activator, an apoptotic agent, e.g., 
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TNF-alpha, TNF-beta, AIMI (See, International Publication 
No. WO 97/33899), AIM II (See, International Publication 
No. WO 97/34911), Fas Ligand (Takahashi et al., Int. Immu 
nol., 6: 1 567-1574 (1994)), VEGI (See, International Publica 
tion No. W0 99/ 23 1 05), a thrombotic agent or an anti-angio 
genic agent, e.g., angiostatin or endostatin; or, biological 
response modi?ers such as, for example, lymphokines, inter 
leukin-1 (“IL-1”), interleukin-2 (“IL-2”), interleukin-6 (“IL 
6”), granulocyte macrophage colony stimulating factor 
(“GM-CSF”), granulocyte colony stimulating factor (“G 
CSF”), or other groWth factors. 
Therapeutic Treatment 
The present invention is further directed to methods for 
preventing and treating hematological malignancies such as 
leukemia. According to the invention, hematological malig 
nancies comprise Without limitation, Hodgkin’s disease, leu 
kemia such as, acute lymphoid (lymphocytic or lymphoblas 
tic) leukemia (ALL), acute myeloid (myelogenous or 
myeloblastic) leukemia (AML), acute lymphoid leukemia, 
biphenotypic (ALL, biphentoypic), acute undifferentiated 
leukemia (AUL), chronic myeloid (myelogenous or granulo 
cytic) leukemia (CML), erythroleukemia, granuloxytic leu 
kemia, lymphoma, monocytic leukemia, myleoma, 
myelomonocytic leukemia, myelodysplastic syndromes, 
non-Hodgkin lymphoma, progranulocytic leukemia. 
Methods of treatment of the present invention comprise 
administering to a subject in need thereof an immunogenic 
composition of the present invention. The compositions may 
be administered With a pharmaceutically acceptable carrier. 
Such pharmaceutical carriers can be sterile liquids, such as 
Water and oils, including those of petroleum, animal, veg 
etable or synthetic origin, such as peanut oil, soybean oil, 
mineral oil, sesame oil and the like. Water is a preferred 
carrier When the pharmaceutical composition is administered 
intravenously. Saline solutions and aqueous dextrose and 
glycerol solutions can also be employed as liquid carriers, 
particularly for injectable solutions. Suitable pharmaceutical 
excipients include starch, glucose, lactose, sucrose, gelatin, 
malt, rice, ?our, chalk, silica gel, sodium stearate, glycerol 
monostearate, talc, sodium chloride, dried skim milk, glyc 
erol, propylene, glycol, Water, ethanol and the like. The com 
position, if desired, can also contain minor amounts of Wet 
ting or emulsifying agents, or pH buffering agents. These 
compositions can take the form of solutions, suspensions, 
emulsion, tablets, pills, capsules, poWders, sustained-release 
formulations and the like. The composition can be formulated 
as a suppository, With traditional binders and carriers such as 
triglycerides. Oral formulation can include standard carriers 
such as pharmaceutical grades of mannitol, lactose, starch, 
magnesium stearate, sodium saccharine, cellulose, magne 
sium carbonate. etc. Examples of suitable pharmaceutical 
carriers are described in “Remington’s Pharmaceutical Sci 
ences” by E. W. Martin. Such compositions Will contain a 
therapeutically effective amount of the compound, preferably 
in puri?ed form, together With a suitable amount of carrier so 
as to provide the form for proper administration to the patient. 
The formulation should suit the mode of administration. 
In a preferred embodiment, the composition is formulated 
in accordance With routine procedures as a pharmaceutical 
composition adapted for intravenous administration to 
human beings. Typically, compositions for intravenous 
administration are solutions in sterile isotonic aqueous buffer. 
Where necessary, the composition may also include a solu 
biliZing agent and a local anesthetic such as lignocaine to ease 
pain at the site of the injection. Generally, the ingredients are 
supplied either separately or mixed together in unit dosage 
form, for example, as a dry lyophiliZed poWder or Water free 
concentrate in a hermetically sealed container such as an 
ampoule or sachette indicating the quantity of active agent. 
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Where the composition is to be administered by infusion, it 
can be dispensed With an infusion bottle containing sterile 
pharmaceutical grade Water or saline. Where the composition 
is administered by injection, an ampoule of sterile Water for 
injection or saline can be provided so that the ingredients may 
be mixed prior to administration. 
The compounds of the invention can be formulated as 
neutral or salt forms. Pharmaceutically acceptable salts 
include those formed With anions such as those derived from 
hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., 
and those formed With cations such as those derived from 
sodium, potassium, ammonium, calcium, ferric hydroxides, 
isopropylamine, triethylamine, 2-ethylamino ethanol, histi 
dine, procaine, etc. 
The amount of the compound of the invention Which Will 
be effective in the treatment, inhibition and prevention of 
hematological malignancies can be determined by standard 
clinical techniques. In addition, in vitro assays may option 
ally be employed to help identify optimal dosage ranges. The 
precise dose to be employed in the formulation Will also 
depend on the route of administration, and the seriousness of 
the disease or disorder, and should be decided according to 
the judgment of the practitioner and each patient’s circum 
stances. Effective doses may be extrapolated from dose-re 
sponse curves derived from in vitro or animal model test 
systems. 
Various other delivery systems are knoWn and can be used 
to administer a composition of the invention, e.g., encapsu 
lation in liposomes, microparticles, microcapsules, recombi 
nant cells capable of expressing the compound, receptor 
mediated endocytosis (See, e.g., Wu and Wu, J. Biol. Chem. 
262:4429-4432 (1987)), construction ofa nucleic acid as part 
of a retroviral or other vector, etc. Methods of introduction 
include but are not limited to intradermal, intramuscular, 
intraperitoneal, intravenous, subcutaneous, intranasal, epidu 
ral, and oral routes. The compounds or compositions may be 
administered by any convenient route, for example by infu 
sion or bolus injection, by absorption through epithelial or 
mucocutaneous linings (e.g., oral mucosa, rectal and intesti 
nal mucosa, etc.) and may be administered together With 
other biologically active agents. Administration can be sys 
temic or local. In addition, it may be desirable to introduce the 
pharmaceutical compounds or compositions of the invention 
into the central nervous system by any suitable route, includ 
ing intraventricular and intrathecal injection; intraventricular 
injection may be facilitated by an intraventricular catheter, for 
example, attached to a reservoir, such as an Ommaya reser 
voir. Pulmonary administration can also be employed, e. g., by 
use of an inhaler or nebuliZer, and formulation With an aero 
soliZing agent. 
In a speci?c embodiment, it may be desirable to administer 
the pharmaceutical compounds or compositions of the inven 
tion locally to the area in need of treatment; this may be 
achieved by, for example, and not by Way of limitation, local 
infusion during surgery, topical application, e.g., in conjunc 
tion With a Wound dressing after surgery, by injection, by 
means of a catheter, by means of a suppository, or by means 
of an implant, said implant being of a porous, non-porous, or 
gelatinous material, including membranes, such as sialastic 
membranes, or ?bers. Preferably, When administering a pro 
tein, including an antibody, of the invention, care must be 
taken to use materials to Which the protein does not absorb. 
In another embodiment, the compound or composition can 
be delivered in a vesicle, in particular a liposome (See Langer, 
Science 249: 1527-1533 (1990); Treat et al., in Liposomes in 
the Therapy of Infectious Disease and Cancer, LopeZ-Berest 
ein and Fidler (eds.), Liss, NeW York, pp. 353-365 (1989); 
LopeZ-Berestein, ibid., pp. 317-327; see generally ibid.) 
In yet another embodiment, the compound or composition 
can be delivered in a controlled release system. In one 
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embodiment, a pump may be used (see Langer, supra; Sefton, 
CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., 
Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321: 
574 (1989)). In another embodiment, polymeric materials can 
be used (see Medical Applications of Controlled Release, 
Langer and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974); 
Controlled Drug Bioavailability, Drug Product Design and 
Performance, Smolen and Ball (eds.), Wiley, NeW York 
(1984); Ranger and Peppas, 1., Macromol. Sci. Rev. Macro 
mol. Chem. 23:61 (1983); see also Levy et al., Science 228: 
190 (1985); During et al., Ann. Neurol. 25:351 (1989); 
HoWard et al., J. Neurosurg. 71:105 (1989)). In yet another 
embodiment, a controlled release system can be placed in 
proximity of the therapeutic target, i.e., the brain, thus requir 
ing only a fraction of the systemic dose (see, e.g., Goodson, in 
Medical Applications of Controlled Release, supra, vol. 2, pp. 
115-138 (1984)). 
In a speci?c embodiment Where the compound of the 
invention is a nucleic acid encoding a protein, the nucleic acid 
can be administered in vivo to promote expression of its 
encoded protein, by constructing it as part of an appropriate 
nucleic acid expression vector and administering it so that it 
becomes intracellular, e.g., by use of a retroviral vector (see 
US. Pat. No. 4,980,286), or by direct injection, or by use of 
microparticle bombardment (e.g., a gene gun; Biolistic, 
Dupont), or coating With lipids or cell-surface receptors or 
transfecting agents, or by administering it in linkage to a 
homeobox-like peptide Which is knoWn to enter the nucleus 
(see e.g., Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864 
1868 (1991)), etc. Alternatively, a nucleic acid can be intro 
duced intracellularly and incorporated Within host cell DNA 
for expression, by homologous recombination. 
EXAMPLES 
The folloWing examples are presented for the illustrative 
purposes and it is to be understood that the present invention 
is not limited to those precise embodiments, and that various 
changes and modi?cations can be effected therein by one 
skilled in the art Without departing from the scope and spirit of 
the invention as de?ned by the appended claims. 
Example 1 
OCT6 Nucleotide Sequence Identi?cation and 
Analysis 
OCT6 Was ?rst identi?ed as a potential OCT gene by 
assembling and sequencing ESTs. BLAST searches of 
human ESTs in GenBank data base identi?ed AI040384 (654 
bP), AA033971 (714 bp) and H70190 (474 bp) sequences 
from three fetal liver IMAGE clones, 1656502, 429904 and 
212935 respectively. IMAGE clone 1656502 (3', insert 1337 
bp) ended the predicted 3' stop codon, Whereas IMAGE clone 
429904 (5', insert 996 bp) and IMAGE clone 212935 (5', 
insert 966 bp) aligned With the 5'-coding region. All clones 
Were obtained from the IMAGE Consortium through the 
American Type Culture Collection (Manassas, Va.). Each 
clone Was sequenced in both directions. The sequences Were 
determined using ABI PrismTM 377 DNA sequencer (Perkin 
Elmer). Our assemblage proved to be identical to the recently 
submitted cDNA OKBl (AF268892) submitted by M. Okabe 
and T. Abe. We have dubbed this gene OCT6 as OCTN1 and 
OCTN2 may be considered as OCT4 and OCT5 respectively. 
The OCT6 gene (SEQ ID NO:1) is also contained Within 
BAC clone CTA-331P3 (SEQ ID NO:3) (GenBank 
AC002464) located at chromosome 6q21. It is divided into 6 
exons that span 42 kb on the human genome, from nucleotide 
79,570 to nucleotide 120490 on CTA-331P3. 
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The gene has a predicted protein structure typical of trans 
port proteins With 2 groups of 6 transmembrane domains 
separated by a hydrophilic region (FIG. 1A). The large hydro 
philic region betWeen TMD1 and TMD2 is typical of OCT 
and OAT genes and is presumed to be located on the outside 
surface of the cell membrane. The OCT6 protein contains 
potential sites for N-glycosylation and phosphorylation, 
Which Will be described beloW in Methods. Of interest, the 
protein sequence also contains a 22 amino acid leucine Zipper 
motif, starting at amino acid 146, suggesting that there may be 
a physical interaction betWeen OCT6 and ion channels or 
other membrane-associated proteins. 
CLUSTALW alignment produced a dendrogram shoWing 
the phylogenic relationship betWeen OCT6 and other OAT 
and OCT proteins (FIG. 1B). This dendrogram suggests that 
the distinction betWeen OAT and OCT genes, based on func 
tional studies, obscures the common origin of both families of 
transporters. The actual CLUSTALW alignment of these 
genes is shoWn in FIG. 2 and demonstrates multiple regions of 
conservation among all of these genes. 
The hydropathy pro?le analysis, multiple sequence align 
ments of amino acid sequences using CLUSTALW and the 
phylogenetic tree Were all produced With MacVector soft 
Ware. 
Example 2 
Molecular Cloning of OCT6 
BLAST searches of human ESTs in GenBank data base 
identi?ed AI040384 (654 bp), AA033971 (714 bp) and 
H70190 (474 bp) sequences from three fetal liver IMAGE 
clones, 1656502, 429904 and 212935 respectively. IMAGE 
clone 1656502 (3', insert 1337 bp) ended the predicted 3' stop 
codon, Whereas IMAGE clone 429904 (5', insert 996 bp) and 
IMAGE clone 212935 (5', insert 966 bp) aligned With the 
5'-coding region. All clones Were obtained from the IMAGE 
Consortium through the American Type Culture Collection 
(Manassas, Va.). Each clone Was sequenced in both direc 
tions. The sequences Were determined using ABI PrismTM 
377 DNA sequencer (Perkin-Elmer). 
Example 3 
Quantitative RT-PCR of OCT6 RNA Levels in 
Cancer Cell Lines 
Total RNA isolated from 50 cell lines used in the NCI drug 
screen program Was provided by the Developmental Thera 
peutics Program, NCI. Quantitative RT-PCR for detecting 
OAT-X transporter gene expression Was performed by using a 
Roche LightCycler, Which uses real time ?uorescence detec 
tion for quantitative measurement of PCR products. A gene 
speci?c primerpair Was designed With Oligo 4.0 softWare and 
purchased from Integrated DNA Technologies, Inc. (Cor 
alville, IoWa) (F: 5'-GGCACATTTATTCACCAAGACCAG 
3') (SEQ ID NO: 13) and (F: 5'-TGTGGACCTCAGCAG 
CATTTGGAT-3') (SEQ ID NO:14). The speci?city of the 
PCR reaction Was con?rmed by directly determining the 
DNA sequence of the PCR product. First, cDNA Was synthe 
siZed from total RNA using SuperScript First-Strand Synthe 
sis System (GIBCO/BRL) in a 20 ul volume folloWing the 
instructions supplied by the manufacturer. The cDNA treated 
With RNAse H for 20 minutes at 370 C. and stored at —200 C. 
Then, 2 ul of cDNA reaction Was ampli?ed in a standard PCR 
reaction condition, using 0.3 uM primer concentration, With 
the addition of SYBR Green I Dye. After 30 seconds denature 
at 950 C., the ampli?cation reaction proceeded through 45-50 
cycles of 950 C. denature for 0 second, 62-650 C. annealing 





































































